Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;18(4):e310821195984.
doi: 10.2174/1573403X17666210831144141.

Novel Non-pharmaceutical Advancements in Heart Failure Management: The Emerging Role of Technology

Mark T Nolan  1   2 , Neville Tan  1 , Christopher J Neil  1   3
Affiliations
Review

Novel Non-pharmaceutical Advancements in Heart Failure Management: The Emerging Role of Technology

Mark T Nolan et al. Curr Cardiol Rev. 2022.

Abstract

Purpose of review: To summarise and discuss the implications of recent technological advances in heart failure care.

Recent findings: Heart failure remains a significant source of morbidity and mortality in the US population despite multiple classes of approved pharmacological treatments. Novel cardiac devices and technologies may offer an opportunity to improve outcomes. Baroreflex Activation Therapy and Cardiac Contractility Remodelling may improve myocardial contractility by altering neurohormonal stimulation of the heart. Implantable Pulmonary Artery Monitors and Biatrial Shunts may prevent heart failure admissions by altering the trajectory of progressive congestion. Phrenic Nerve Stimulation offers potentially effective treatment for comorbid conditions. Smartphone applications offer an intriguing strategy for improving medication adherence.

Summary: Novel heart failure technologies offer promise for reducing this public health burden. Randomized controlled studies are indicated for assessing the future role of these novel therapies.

Keywords: Heart failure; baroreflex activation therapy; biatrial shunts; cardiac contractility; cardiac device; modulation healthcare mobile phone applications; phrenic nerve stimulation; pulmonary artery pressure monitoring; technology.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Images demonstrating the appearance and physical characteristics of the novel heart failure devices discussed in main text. The devices are not shown to scale. And include: A) CardioMEMs implantable pulmonary artery monitor (Abbott Inc., Atlanta USA); B) BarostimNEO baroreflex activation therapy device (CVRx Inc., Minneapolis USA); C) Remede phrenic nerve stimulator (Respicardia Inc., Minnetonka USA); D) Optimizer Smart (Impulse Dynamics Inc., New York USA); E) V-Wave interatrial shunt (V Wave Inc., Caesarea Israel)
Fig. (2)
Fig. (2)
Suggested scheme for identifying patients in clinical practice that might benefit from utilization of a novel cardiac device to improve their heart failure symptoms and trajectory, and may assist in matching patient subgroups to devices with demonstrated benefit to that subgroup
Fig. (3)
Fig. (3)
Timeline of large clinical trials of novel cardiac devices for heart failure, including important studies scheduled for publication in the upcoming years.
See this image and copyright information in PMC

References

    1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., Bravata D.M., Dai S., Ford E.S., Fox C.S., Fullerton H.J., Gillespie C., Hailpern S.M., Heit J.A., Howard V.J., Kissela B.M., Kittner S.J., Lackland D.T., Lichtman J.H., Lisabeth L.D., Makuc D.M., Marcus G.M., Marelli A., Matchar D.B., Moy C.S., Mozaffarian D., Mussolino M.E., Nichol G., Paynter N.P., Soliman E.Z., Sorlie P.D., Sotoodehnia N., Turan T.N., Virani S.S., Wong N.D., Woo D., Turner M.B. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–e220. - PMC - PubMed
    1. Blecker S., Paul M., Taksler G., Ogedegbe G., Katz S. Heart failure–associated hospitalizations in the United States. J. Am. Coll. Cardiol. 2013;61(12):1259–1267. doi: 10.1016/j.jacc.2012.12.038. - DOI - PMC - PubMed
    1. Armstrong P.W., Pieske B., Anstrom K.J., Ezekowitz J., Hernandez A.F., Butler J., Lam C.S.P., Ponikowski P., Voors A.A., Jia G., McNulty S.E., Patel M.J., Roessig L., Koglin J., O’Connor C.M. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med. 2020;382(20):1883–1893. doi: 10.1056/NEJMoa1915928. - DOI - PubMed
    1. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., Zile M.R. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014;371(11):993–1004. doi: 10.1056/NEJMoa1409077. - DOI - PubMed
    1. Yancy C.W., Januzzi J.L., Jr, Allen L.A., Butler J., Davis L.L., Fonarow G.C., Ibrahim N.E., Jessup M., Lindenfeld J., Maddox T.M., Masoudi F.A., Motiwala S.R., Patterson J.H., Walsh M.N., Wasserman A. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the american college of cardiology task force on expert consensus decision pathways. J. Am. Coll. Cardiol. 2018;71(2):201–230. doi: 10.1016/j.jacc.2017.11.025. - DOI - PubMed

LinkOut - more resources